A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of BMS-911543 in Subjects With Myelofibrosis.

Trial Profile

A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of BMS-911543 in Subjects With Myelofibrosis.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Mar 2017

At a glance

  • Drugs BMS 911543 (Primary)
  • Indications Myelofibrosis
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 Feb 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 15 Sep 2014 Planned End Date changed from 1 Jan 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top